Indaptus Therapeutics, Inc. Announces Significant Executive and Board Changes

Key Points:

• Appointment of Yu Ding as Chief Financial Officer, effective April 1, 2026.
• Resignation of Matthew McMurdo from the Audit Committee.
• Appointment of Qinglai Lu and Jerome Abbour to the Audit Committee.
• Yu Ding brings extensive international financial expertise, previously serving as CFO and VP for major Shanghai and Hong Kong listed companies.

Details of the Changes

Indaptus Therapeutics, Inc. (NASDAQ: INDP), a clinical-stage biopharmaceutical company based in New York City, has filed a Form 8-K reporting material changes to its executive management and board composition.

New Chief Financial Officer: Yu Ding

On April 1, 2026, the Board of Directors appointed Mr. Yu Ding as Chief Financial Officer (CFO) of the company, effective immediately. This appointment follows a thorough review of his qualifications, marking a pivotal moment for the company as it continues its growth and international expansion.

Yu Ding, aged 51, is a financial executive with over 20 years of experience in commercial and financial markets. His expertise includes capital management, strategic financial planning, and leadership across sectors. Notably, he has significant experience navigating complex regulatory environments for publicly traded companies in China and Hong Kong.

Prior to joining Indaptus Therapeutics, Mr. Ding served as Vice President and CFO of Grand Auto Service Group Co., Ltd. (600297.SS), a Shanghai Stock Exchange-listed company, from August 2023 to January 2026. He also held the CFO position at Grand Baoxin Auto Group Limited, listed on the Hong Kong Stock Exchange during the same period. Additionally, he was Vice President of China ZhengTong Auto Services Holdings Limited (1728.HK) in Hong Kong from May 2019 to December 2019.

Mr. Ding graduated from Shanghai Jiao Tong University in 1999 with a Bachelor’s degree in Communication Engineering and has been a Chartered Financial Analyst (CFA) charterholder since 2005.

Audit Committee Changes

On March 31, 2026, Matthew McMurdo resigned from his position as a member of the Audit Committee. The Board subsequently appointed Qinglai Lu and Jerome Abbour as new members, further strengthening the company’s oversight and governance structure.

Implications for Shareholders

Potential Share Price Impact:

• The appointment of a seasoned CFO with extensive international and capital market experience may signal a renewed focus on financial discipline and global expansion. This could positively influence investor sentiment and share valuation, particularly as the company seeks to execute its clinical and commercial strategies.
• Changes to the audit committee enhance corporate governance and may reassure investors regarding the integrity of financial reporting and controls.
• There were no written communications, soliciting materials, or pre-commencement tender offers associated with this filing, indicating no immediate transactions or special communications that could impact the share price.

Other Notable Facts:

• Indaptus Therapeutics is not classified as an emerging growth company, implying it is subject to full financial reporting and compliance requirements.
• The company’s common stock, \$0.01 par value, is listed on the Nasdaq Capital Market under the ticker symbol “INDP”.

Conclusion:
The executive and board changes announced by Indaptus Therapeutics, Inc. in this Form 8-K filing represent significant developments. The addition of Yu Ding as CFO, with his robust international experience and leadership in public companies, may be viewed as a strategic move to bolster financial management and corporate growth. The reshuffling of the audit committee also signals enhanced corporate governance. Investors should monitor these changes closely, as they may have implications for future company performance and share price.

Disclaimer:
This article is provided for informational purposes only and does not constitute investment advice. Investors are urged to conduct their own due diligence and consult with financial advisors before making any investment decisions. The information herein is based on a public SEC filing and is subject to change or update without notice.

View Indaptus Therapeutics, Inc. Historical chart here